Table 3. Selected ongoing clinical trials in small bowel adenocarcinoma. Ref: www.clinicaltrials.gov.

Clinicaltrials.gov	Title	Treatment	Phase	Primary outcome measure	Sponsor/Collaborators	Anticipated completion date
NCT01202409	Phase II Study of Panitumumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater	Capecitabine 750 mg/m2 bid × 14 days, Oxaliplatin 130 mg/m2 day 1 and Panitumumab 9 mg/kg day 1 every 21 day cycle	II	Response Rate	M.D. Anderson Cancer Center/Amgen	Nov-14
NCT00433550	A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan (I), Oxaliplatin (O), and Capecitabine (C) as First-Line Therapy for Advanced Small Bowel Adenocarcinoma	Group 1 (6/6 UGT1A1 genotype): I (d1)+O (d1)+C (d2-15). Group 2 (6/7): I as group 1, Lower doses of O and C. Group 3 (7/7): I, O and C at lower doses	II	Tumor response after 12 courses of study treatment	North Central Cancer Treatment Group/National Cancer Institute (NCI)	Dec-12
NCT01208103	Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater	Capecitabine 750 mg/m2 bid × 14 days, Oxaliplatin 130 mg/m2 day 1 and Bevacizumab 7.5 mg/kg day 1 every 21 day cycle	II	Progression free survival	M.D. Anderson Cancer Center/Genentech	May-15
NCT00987766	Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. (includes Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer)	Erlotinib by mouth daily 6 days every other week, Gemcitabine IV every other week, Oxaliplatin IV every other week	I	MTD and recommended phase II dose of erlotinib in combination with gemcitabine and oxaliplatin	Vanderbilt-Ingram Cancer Center/National Cancer Institute (NCI)	Jan-16